Startup profile for Samphire Neuroscience: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Samphire Neuroscience funding, valuation and investors

Wearable neurotechnology focused on women's menstrual health.

Verified company research · funding, investors and latest developments

Keep track of Samphire Neuroscience

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$5M · June 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$7.3M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · London, United Kingdom

Investors in latest funding

Lead: Fortify Ventures , Inventure

Other: Ayuh Ventures , APEX , SOSV , Afterwork Ventures , FIRSTPICK , Seaside Ventures

Sources: latest funding · paaomasijoittajat.fi Last verified: 2026-11-15

Overview

Samphire Neuroscience develops wearable brain-stimulation technology for women's health. Its Nettle device is designed around menstrual-related mood and pain symptoms. The company announced a $2.3 million pre-seed financing in February 2024 and a $5 million seed financing in 2025. Ayuh Ventures was named in both rounds. Funding figures describe the entire rounds; Ayuh's individual investment was not disclosed.

Why Samphire Neuroscience is interesting

Samphire brings medical-device development to an underserved health category. Its commercial progress depends on clinical evidence, regulatory permissions, patient access and distribution, alongside the practical usability of the wearable.

Product & use cases

Nettle is a head-worn neuromodulation device. Samphire's company history describes UK and EU Class IIa medical-device clearance. The 2025 financing announcement said capital would support commercialization and further clinical development. Regulatory permissions and approved uses vary by market.

  • Development of wearable approaches to menstrual-related symptoms.
  • Clinical and distribution partnerships in women's health.

Key facts

  • Ayuh named in the 2024 pre-seed and 2025 seed announcements.
  • The 2025 seed was co-led by Fortify Ventures and Inventure.
  • Company describes Nettle's UK and EU Class IIa clearance; no US approval is implied.

Funding history (newest first)

Seed

2025-06 $5M
  • Fortify Ventures (lead)
  • Inventure (lead)
  • Ayuh Ventures (participant)
  • APEX (participant)
  • SOSV (participant)
  • Afterwork Ventures (participant)
  • FIRSTPICK (participant)
  • Seaside Ventures (participant)

Source: Read source · paaomasijoittajat.fi

Pre-Seed

2024-02 $2.3M
  • Ayuh Ventures (participant)
  • SOSV (participant)
  • FIRSTPICK (participant)
  • Afterwork (participant)
  • Seaside (participant)
  • CVX Ventures (participant)

Source: Read source · firstpick.vc

Investors in our directory

Funds linked from Samphire Neuroscience's profile — open a fund page for stage focus and related deal articles.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Samphire Neuroscience

Practical answers founders, operators, and investors typically search for.

Public announcements describe a $2.3M pre-seed round in February 2024 and a $5M seed round in 2025. These are round totals, not Ayuh's individual checks.
Fortify Ventures and Inventure co-led. APEX and returning investors including Ayuh, SOSV, Afterwork, FIRSTPICK and Seaside participated.
It develops wearable neurotechnology, including Nettle, for women's health. Product and regulatory information should be checked at https://www.samphireneuro.com/about.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.